News
- Author:
- Mary Ellen Schneider
Publish date: April 4, 2018
Following the FDA’s lead, the European Commission approves denosumab for prevention of skeletal-related events.
News
- Author:
- Mary Ellen Schneider
Publish date: April 2, 2018
The presence of molecular minimal residual disease, despite complete remission, could be an independent predictor of future relapse risk.
Video
- Author:
- Mary Ellen Schneider
Publish date: March 27, 2018
LA JOLLA, CALIF. – Dr. Steven Horwitz says the key to preparing patients for transplant is “good remission.”
News
- Author:
- Mary Ellen Schneider
Publish date: March 23, 2018
The decision expands the drug’s indication to include first- and second-line use in children.
News
- Author:
- Mary Ellen Schneider
Publish date: March 20, 2018
The approval is based on results from the ECHELON-1 trial in previously untreated patients with stage III or IV classical Hodgkin lymphoma.
News
- Author:
- Mary Ellen Schneider
Publish date: March 14, 2018
Dr. Leonid Yavorkovsky of Kaiser Permanente San Jose Medical Center questions the traditional approach to treatment of class mantle cell lymphoma.<...
News
- Author:
- Mary Ellen Schneider
Publish date: March 13, 2018
Infants and children with secondary diabetes mellitus were among those most likely to develop steroid-induced hypertension.
News
- Author:
- Mary Ellen Schneider
Publish date: March 8, 2018
Emicizumab is now approved in Europe and the United States for routine prophylaxis of bleeding episodes in people with factor VIII inhibitors.
News
- Author:
- Mary Ellen Schneider
Publish date: March 7, 2018
The two new tests will screen whole blood and plasma samples.
News
- Author:
- Mary Ellen Schneider
Publish date: February 27, 2018
The trial is expected to enroll 40 adult ALL patients in complete remission with positive minimal residual disease.
News
- Author:
- Mary Ellen Schneider
Publish date: February 21, 2018
The FDA has granted breakthrough therapy designation to a gene therapy product aimed at hemophilia A.
News
- Author:
- Mary Ellen Schneider
Publish date: February 20, 2018
The FDA is expected to make a decision in August 2018.
News
- Author:
- Mary Ellen Schneider
Publish date: February 6, 2018
Celgene announced the phase 3 trial results, which investigators intend to present at future meetings.
News
- Author:
- Mary Ellen Schneider
Publish date: February 6, 2018
The drug was approved by the U.S. Food and Drug Administration in November 2017.
News
- Author:
- Mary Ellen Schneider
Publish date: January 31, 2018
The study evaluated more than 600 adults with newly diagnosed multiple myeloma who relapsed.
